429 related articles for article (PubMed ID: 34762222)
1. Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS.
Brückner L; Beyer-Westendorf J; Tiebel O; Pietsch J
J Thromb Thrombolysis; 2022 May; 53(4):777-787. PubMed ID: 34762222
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an ultra-high performance liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of direct oral anticoagulants in human plasma.
Zhang YF; Liu XQ; Wang Y; Xu X; Zhong MK; Zhang P; Ma CL
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122952. PubMed ID: 34598085
[TBL] [Abstract][Full Text] [Related]
3. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
5. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
[TBL] [Abstract][Full Text] [Related]
7. Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.
Boehr S; Haen E
Ther Drug Monit; 2017 Feb; 39(1):66-76. PubMed ID: 27861316
[TBL] [Abstract][Full Text] [Related]
8. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
[TBL] [Abstract][Full Text] [Related]
10. UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.
Kuhn J; Gripp T; Flieder T; Dittrich M; Hendig D; Busse J; Knabbe C; Birschmann I
PLoS One; 2015; 10(12):e0145478. PubMed ID: 26699714
[TBL] [Abstract][Full Text] [Related]
11. Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
Gouveia F; Bicker J; Santos J; Rocha M; Alves G; Falcão A; Fortuna A
J Pharm Biomed Anal; 2020 Mar; 181():113109. PubMed ID: 31981828
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.
Harenberg J; Beyer-Westendorf J; Crowther M; Douxfils J; Elalamy I; Verhamme P; Bauersachs R; Hetjens S; Weiss C;
Thromb Haemost; 2020 Jan; 120(1):132-140. PubMed ID: 31705521
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
Lindahl S; Dyrkorn R; Spigset O; Hegstad S
Ther Drug Monit; 2018 Jun; 40(3):369-376. PubMed ID: 29578938
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Noguez JH; Ritchie JC
Methods Mol Biol; 2016; 1383():21-7. PubMed ID: 26660170
[TBL] [Abstract][Full Text] [Related]
15. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
[TBL] [Abstract][Full Text] [Related]
16. Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study.
Merrelaar AE; Bögl MS; Buchtele N; Merrelaar M; Herkner H; Schoergenhofer C; Harenberg J; Douxfils J; Siriez R; Jilma B; Spiel AO; Schwameis M
Thromb Haemost; 2022 Oct; 122(10):1723-1731. PubMed ID: 35785816
[TBL] [Abstract][Full Text] [Related]
17. Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
Wiesen MHJ; Blaich C; Streichert T; Michels G; Müller C
Clin Chem Lab Med; 2017 Aug; 55(9):1349-1359. PubMed ID: 28328524
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry.
Zhang M; Moore GA; Chin PKL
Ther Drug Monit; 2020 Jun; 42(3):473-480. PubMed ID: 32053549
[TBL] [Abstract][Full Text] [Related]
19. Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
Baldelli S; Cattaneo D; Pignatelli P; Perrone V; Pastori D; Radice S; Violi F; Clementi E
Bioanalysis; 2016 Feb; 8(4):275-83. PubMed ID: 26808218
[TBL] [Abstract][Full Text] [Related]
20. DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation.
Margetić S; Ćelap I; Huzjan AL; Puretić MB; Goreta SŠ; Glojnarić AČ; Brkljačić DD; Mioč P; Harenberg J; Hetjens S; Weiss C
Thromb Haemost; 2022 Sep; 122(9):1542-1548. PubMed ID: 35088395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
